<DOC>
	<DOCNO>NCT00883675</DOCNO>
	<brief_summary>The purpose study determine whether safe treat lung cancer patient undergone attempt curative resection combination docetaxel carboplatin .</brief_summary>
	<brief_title>Safety Study Adjuvant Docetaxel-Carboplatin Treatment Resected Lung Cancer</brief_title>
	<detailed_description>Patients stage Ib - IIIa NSCLC participate open-label , single arm study assess safety tolerability docetaxel ( 75 mg/kg ) carboplatin ( AUC 5.5 ) administer 3 cycle resection curative intent . The primary endpoint study safety , reflect febrile neutropenia rate &lt; 10 % . Other endpoint assess protocol compliance impact minimally invasive surgical technique .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Nonsmall cell lung cancer stage IB IIIA , complete resection mediastinal lymph node dissection ECOG status 01 &gt; 14 &lt; 56 day since resection Prior chemotherapy and/or radiation therapy lung cancer Peripheral neuropathy &gt; grade 1 Concurrent malignancy , basal cell squamous cell carcinoma skin carcinoma situ cervix Medical condition permit treatment follow accord protocol Prior treatment docetaxel carboplatin Hypersensitivity polysorbate 80 , platinumcontaining compound mannitol Treatment investigational anticancer drug within 30 day registration Pregnant nursing woman HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>Adjuvant therapy</keyword>
</DOC>